The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

As per The Business Research Company’s RNA Targeting Small Molecule Drug Discovery Global Market Report 2023, The global RNA targeting small molecule drug discovery market is expected to grow from $1.18 billion in 2022 to $1.45 billion in 2023 at a compound annual growth rate (CAGR) of 23.3%. The RNA targeting small molecule drug discovery market is expected to reach $3.21 billion in 2027 at a CAGR of 21.9%.

What was the major driver in the RNA targeting small molecule drug discovery market?
The increasing prevalence of cancer, genetic disorders, and viral infections is expected to propel the growth of the RNA-targeted small-molecule drug discovery market going forward. Cancer is a group of diseases characterized by the uncontrollable growth of cells in the body. Viral infections refer to infections caused by viruses, tiny infectious agents that can only replicate inside the cells of living organisms. For instance, in February 2021, according to the American Cancer Society, a US-based voluntary Health Organization, there were approximately 19.3 million new cancer cases and 10 million cancer deaths in 2020. The number is expected to increase by 47% by 2040, reaching about 28.4 million cases. Furthermore, in 2021, according to the World Health Organization, a Switzerland-based specialized health agency of the United Nations, approximately 38.4 million people were living with HIV, and 650,000 people died due to HIV. Therefore, the increasing prevalence of cancer, genetic disorders, and viral infections drives the growth of the RNA-targeted small-molecule drug discovery market.

View More On The RNA Targeting Small Molecule Drug Discovery Market Report 2023 – https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

What was the key trend in the RNA targeting small molecule drug discovery market?
Artificial intelligence (AI) integration in drug discovery is a key trend gaining popularity in the RNA targeting small molecule drug discovery market. Major companies in the RNA targeting small molecule drug discovery market are leveraging AI technology to accelerate drug discovery procedures to sustain their position in the market. For instance, in May 2023, Google Cloud, the cloud computing suite of Google, a US-based technology company, launched Target and Lead Identification Suite and Multiomics Suite to facilitate the drug discovery process. The Multiomics Suite expedites the identification and analysis of genetic data, assisting businesses in designing precision medicines. The Target and Lead Identification Suite aids researchers in better understanding the role of amino acids and predicting the structure of proteins.

Which was the largest region in the RNA targeting small molecule drug discovery market?
North America was the largest region in the RNA targeting small molecule drug discovery market in 2022. The regions covered in RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the RNA targeting small molecule drug discovery market prominent players?
Major players in the RNA targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd , Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, and Expansion Therapeutics.

Key RNA targeting small molecule drug discovery market segments
The global RNA targeting small molecule drug discovery market is segmented –
1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies
3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Request A Sample Of The Global RNA Targeting Small Molecule Drug Discovery Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12480&type=smp

The RNA Targeting Small Molecule Drug Discovery Global Market Report 2023  provides a comprehensive overview on the RNA targeting small molecule drug discovery market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Drug Discovery Services Global Market Report 2023
Drug Discovery Global Market Report 2023
Virtual Clinical Trials Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model